Trial data show up to 30% of patients achieved complete response and 70% demonstrated some benefit from treatment.
Mark Jackson, MD
Advertisement
Articles by Mark Jackson, MD
Advertisement
Latest Updated Articles
Phase 2 Trial Highlights Efficacy of Novel Urticaria TherapyPublished: October 2nd 2025 | Updated:
Advertisement
Advertisement
Trending on Dermatology Times
1
Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
2
Top 5 Articles of the Week: November 30-December 5
3
The Weekly Roundup: December 1-5
4
DeepSeek-R1 Outperforms ChatGPT-4o in Urticaria Clinical Queries
5
